The Australian pharmaceutical group confirmed on Monday that a takeover of Boots would not meet its strategic and capital investment objectives, according to a company statement reported by the Guardian. The decision removes the most prominent suitor from a sales process that Walgreens Boots Alliance (NASDAQ: WBA) has struggled to conclude for several years.
For the 1,800 UK stores that trade under the Boots name, and for the thousands of SME suppliers and landlords connected to that estate, the collapsed deal raises a pointed question: who, if anyone, is willing to pay £7bn for a high-street pharmacy network in its current form?
Why Sigma walked away
Sigma Healthcare merged with Chemist Warehouse in 2024 to create Australia's largest pharmacy group, a combination that gave the enlarged business the scale and ambition to consider international expansion. A Boots acquisition would have represented a significant step into the UK market, adding a storied retail brand and a vast dispensing network to its portfolio.
But the numbers, it appears, did not add up. Sigma cited a misalignment between the proposed deal and its strategic and capital investment objectives, as first reported by the Guardian. The company offered no further detail on which specific elements of the transaction proved unacceptable.
Several factors likely weighed on Sigma's assessment. The UK pharmacy sector operates under persistent margin pressure from NHS funding constraints. Dispensing fees, which form a substantial share of pharmacy revenue, have not kept pace with rising operating costs including wages, energy, and business rates. At the same time, online dispensing services continue to erode footfall at physical pharmacies, chipping away at the ancillary retail sales that help subsidise dispensing activity.
For a buyer based in Australia, currency risk and the complexity of integrating a 1,800-store UK operation with an antipodean wholesale and retail business would have added further layers of difficulty. At a reported price tag of $10bn, the margin for error was slim.
Boots's long search for a new owner
The collapse of the Sigma talks is not the first time a Boots sale has fallen through. Walgreens Boots Alliance explored a sale or partial exit from the UK business as far back as 2022, launching a formal process that attracted interest from private equity firm Apollo Global Management and Indian conglomerate Reliance Industries, among others.
That process stalled without a deal. Reported valuations at the time ranged widely, and bidders struggled to reconcile the asking price with the operational realities of running a large UK pharmacy chain. The gap between seller expectations and buyer willingness has remained a persistent obstacle.
Walgreens Boots Alliance, which acquired full ownership of Boots in 2014, has faced its own strategic pressures in the United States, including store closures, opioid-related litigation costs, and a broader rethink of its retail pharmacy model. A Boots disposal would have freed capital and simplified the group's structure, but only at the right price.
The Sigma approach, which emerged publicly in recent months, appeared to offer a credible route to a transaction. The merged Sigma-Chemist Warehouse entity had both the pharmacy expertise and the stated growth ambitions to make the deal plausible. Its withdrawal narrows the field considerably.
What the failed deal means for UK pharmacy
The immediate practical impact on Boots's day-to-day operations is limited. Stores will continue to trade, prescriptions will be dispensed, and supplier contracts will be honoured. Walgreens Boots Alliance remains the owner and has not signalled any intention to wind down the UK business.
But prolonged ownership uncertainty carries real costs. Strategic investment decisions, including store refurbishments, technology upgrades, and network rationalisation, tend to stall when a business is perpetually on the market. Suppliers, particularly smaller wholesalers and own-label manufacturers, face difficulty planning around a customer whose long-term direction is unclear.
For landlords with Boots as a tenant, the situation is similarly uncomfortable. Boots occupies prime and secondary high-street locations across the UK. A change of ownership could trigger lease renegotiations, store closures, or format changes. The absence of a deal does not resolve that risk; it merely defers it.
The broader UK pharmacy sector, meanwhile, continues to consolidate. Independent pharmacies have been closing at a steady rate, squeezed by the same funding and cost pressures that complicate the Boots valuation. Community pharmacy contractors dispensed over one billion prescription items in England in the 2023-24 financial year, according to NHS Business Services Authority data, yet many operators report operating at or near breakeven on dispensing alone.
A well-capitalised new owner for Boots could, in theory, invest in the network and stabilise a significant portion of the UK's pharmacy infrastructure. Without one, the chain's trajectory depends on the priorities of a parent company with its own challenges an ocean away.
Who else could buy Boots?
The pool of realistic acquirers is not large. A deal of this scale, roughly £7bn, rules out most trade buyers in the UK pharmacy sector. None of the major UK pharmacy chains, including LloydsPharmacy's successor operations or Well Pharmacy, has the balance sheet to contemplate a transaction of this size.
Private equity remains a possibility. Apollo was among the interested parties in the 2022 process, and large buyout firms have historically been willing to acquire complex retail and healthcare assets at the right price. However, the current interest rate environment, while lower than its 2023 peak, still makes highly leveraged acquisitions of low-margin retail businesses a challenging proposition.
International pharmaceutical distributors and retailers could re-enter the frame. McKesson Corporation, the US-based pharmaceutical distributor, and European groups such as Phoenix Group or BPAS have the sector expertise, though none has publicly expressed interest.
Reliance Industries, the Indian conglomerate controlled by Mukesh Ambani, was linked to the 2022 process and has continued to expand its retail operations in India. Whether it would revisit a Boots bid is unclear.
There is also the possibility that Walgreens Boots Alliance opts for a partial solution: spinning off Boots as a separately listed entity, selling a minority stake to a financial partner, or pursuing a phased disposal. Each carries its own complexity, but a full sale at the desired valuation appears increasingly difficult to achieve.
For now, Boots remains in a holding pattern. The brand retains significant consumer recognition, a large store footprint, and a central role in UK community pharmacy. What it lacks is a clear ownership trajectory, and the Sigma withdrawal has made that gap harder to close.
